

1 **A modified ZSM-5 zeolite/Fe₂O₃ composite as a sorbent for magnetic**
2 **dispersive solid-phase extraction for the preconcentration of nonsteroidal**
3 **anti-inflammatory drugs in water and urine samples†**

4
5 Paola Baile, Lorena Vidal* and Antonio Canals*

6 Departamento de Química Analítica, Nutrición y Bromatología e Instituto

7 Universitario de Materiales, Universidad de Alicante, P.O. Box 99, E-03080

8 Alicante, Spain.

9 * Corresponding authors: Tel.: +34965909790; fax: +34965903697.

10 E-mail addresses: lorena.vidal@ua.es (L. Vidal), a.canals@ua.es (A. Canals).

11 † Electronic supplementary information (ESI) available.

12
13 **Abstract**

14 This study is the first to use a new ZSM-5 zeolite-based composite
15 decorated with iron oxide magnetic nanoparticles and modified with
16 hexadecyltrimethylammonium bromide surfactant (i.e., HDTMA-ZSM-5/Fe₂O₃)
17 as an efficient sorbent for magnetic dispersive solid-phase extraction (MDSPE)
18 of nonsteroidal anti-inflammatory drugs in water and urine samples with
19 subsequent measurement by liquid chromatography diode array detection.
20 Experimental factors affecting MDSPE were optimized using a multivariate
21 optimization strategy. The optimum experimental conditions were: amount of
22 sorbent, 40 mg; sample pH, 2.2; NaCl concentration, 2.5%; extraction time, 2
23 min; eluent solvent, methanol; eluent solvent volume, 424 µL; and elution time,
24 2 min. The linearity of the method was studied from 3.3 to 400 µg L⁻¹ (N=8) for
25 ketoprofen, from 1.7 to 400 µg L⁻¹ (N=8) for felbinac, from 6.6 to 400 µg L⁻¹

26 (N=7) for diclofenac and from 9.9 to 400 $\mu\text{g L}^{-1}$ (N=6) for ibuprofen. Method
27 repeatability was evaluated at 10 and 200 $\mu\text{g L}^{-1}$ spiking levels, obtaining
28 coefficients of variation between 2 and 5% (n=6). Limits of detection,
29 determined empirically, were 1.0 $\mu\text{g L}^{-1}$, 0.5 $\mu\text{g L}^{-1}$, 2.0 $\mu\text{g L}^{-1}$ and 3.0 $\mu\text{g L}^{-1}$ for
30 ketoprofen, felbinac, diclofenac and ibuprofen, respectively. Tap water,
31 reservoir water, wastewater and five urine samples were selected to assess
32 method applicability. Recovery values ranged between 86-107% and 80-112%
33 for water and urine samples, respectively, showing negligible matrix effects.
34 Finally, this method was employed to monitor ibuprofen excretion in real urine
35 samples.

36

37 **Keywords:** zeolite, surfactant, magnetic dispersive solid-phase extraction,
38 nonsteroidal anti-inflammatory drugs, water samples, urine samples.

39

40 **1. Introduction**

41 Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely
42 used medications worldwide due to their analgesic, antipyretic and anti-
43 inflammatory properties [1]. These drugs are used to treat chronic pain,
44 osteoarthritis, rheumatoid arthritis, gout, dysmenorrhea, dental pain and
45 headache [2]. NSAIDs are readily available over-the-counter without medical
46 prescription. Short-term NSAIDs usage is believed safe; however, acute
47 overdose or chronic abuse can cause adverse side-effects such as
48 gastrointestinal bleeding, acute kidney injury and cardiovascular risk [3]. To
49 diagnose cases of acute overdose or chronic abuse or, more importantly,
50 assess differential diagnostic exclusion, an analytical procedure is required to

51 detect these drugs in human urine prior to their quantitation in plasma.
52 Therefore, determination of drugs in urine is essential to monitor drugs
53 concentration [4]. Moreover, NSAIDs are continually being loaded into waters,
54 mainly indirectly by excreta, through disposal of unused or expired drugs, or
55 directly in discharges from pharmaceutical-manufacturing plants [5]. The
56 release of these NSAIDs residues into environmental aqueous systems is toxic
57 to many animal species and human beings. Several NSAIDs have been
58 detected in wastewaters and rivers [6–9], showing the need for NSAIDs
59 monitoring in aqueous environments. All the above reasons show the
60 importance of developing a simple and fast method to determine NSAIDs in
61 environmental (e.g., water) and biological samples (e.g., urine) in order to
62 prevent negative health effects.

63 NSAIDs are usually determined by chromatographic techniques such as
64 gas chromatography (GC) [6,10], liquid chromatography (LC) [7–9,11,12] or
65 capillary electrophoresis [13] combined with different detectors. Since GC
66 requires a previous derivatization step [6,10], separation is typically performed
67 by LC. However, direct determination of NSAIDs in environmental and biological
68 samples is problematic due to their low concentration and matrix complexity,
69 making a sample pretreatment step necessary prior to chromatographic
70 analysis. Solid-phase extraction is the most commonly used sample
71 pretreatment procedure to determine NSAIDs [14] using different sorbents such
72 as C₁₈ [15], modified polymers [16,17], molecular imprinted polymers (MIPs)
73 [12,18] and carbon nanotubes (CNTs) [19]. However, the original SPE has
74 undergone numerous modifications to date, mainly related to miniaturization or
75 automatization [20]. Different modalities of miniaturized SPE such as solid-

76 phase microextraction (SPME) [21–24], stir-bar sorptive extraction (SBSE)
77 [25,26] and microextraction by packed sorbent (MEPS) [27,28] have also been
78 used for the determination of NSAIDs. Magnetic dispersive solid-phase
79 extraction (MDSPE), also called magnetic solid phase extraction (MSPE), uses
80 magnetic or magnetically modified sorbents. This method, having first been
81 used for analytical purposes by Šafaříková and Šaferčík in 1999 [29], has
82 recently become popular because it reduces sample preparation time and
83 facilitates sorbent manipulation [20,30]. In MDSPE, the magnetic sorbent is
84 directly added and dispersed in the sample solution. After extraction, the
85 magnetic sorbent is easily separated from the sample by using an external
86 magnetic field (i.e., neodymium magnet) without requiring filtration or
87 centrifugation steps and thus reducing time and energy [30]. This makes the
88 extraction process simpler, faster and portable. Finally, analytes can be eluted
89 using a proper solvent or thermally desorbed for further determination. Some
90 works describe magnetic materials used as sorbent, such as magnetic
91 melamine-formaldehyde resin [31], modified magnetic nanoparticles [32,33],
92 magnetic graphene composite [34,35], magnetic sporopollenin-
93 cyanopropyltriethoxysilane [36], and magnetic metal organic framework [9], for
94 determination of NSAIDs in environmental and biological samples. However, to
95 our knowledge there are no reported methods based on MDSPE using zeolites
96 modified with magnetic nanoparticles as sorbent for preconcentration of
97 NSAIDs [37].

98 Zeolites are ordered crystalline aluminosilicates constituted by a framework
99 structure composed of TO_4 tetrahedra (T= Si, Al) interconnected through O [38].
100 The presence of Al atoms into the structure makes the framework negatively

101 charged due to the difference between the $(\text{AlO}_4)^{5-}$ and $(\text{SiO}_4)^{4-}$ tetrahedral. This
102 negative charge is compensated by extraframework cations (e.g., alkaline and
103 alkaline earth) [37–40]. These materials possess unique and fascinating
104 properties such as high surface area, high adsorption capacity and molecular
105 selectivity, chemical and thermal stability, ion-exchange capacity, low cost
106 extraction and synthesis. Additionally, ease of modification provides a wide
107 range of zeolite-based materials, which convert zeolites into potential sorbents
108 for extraction procedures. In many cases, zeolites cannot adsorb organic
109 molecules because its pore size is smaller than the dimensions of organic
110 compounds. For this reason, in order to increase organic compounds
111 preconcentration capacity, zeolites have been modified with cationic
112 surfactants. The cationic surfactants commonly used to modify zeolites are long
113 alkyl chains with a quaternary ammonium group at one end of the chain. Since
114 the channel diameter of the zeolite is considered sufficiently large for
115 exchangeable cations, but too small for the cationic surfactant, the sorption of
116 surfactant molecules on zeolite is limited to the external surface sites [41].
117 Several publications have reported the use of cationic surfactant modified
118 zeolites to determine organic compounds [42–45]. However, to our knowledge
119 there are no published methods with analytical purposes to extract NSAIDs by
120 magnetic zeolites modified with cationic surfactants [37].

121 Therefore, this work aims to develop a simple MDSPE method, employing a
122 ZSM-5 zeolite-based composite decorated with iron oxide magnetic
123 nanoparticles and modified with hexadecyltrimethylammonium bromide
124 surfactant (i.e., HDTMA-ZSM-5/ Fe_2O_3) as a valuable sorbent for the
125 simultaneous separation and preconcentration of four NSAIDs (i.e., ketoprofen,

126 felbinac, diclofenac and ibuprofen) (Table S1) from both water and urine
127 samples for subsequent separation/quantification by liquid chromatography-
128 diode array detection (LC-DAD). To our knowledge, this is the first report of an
129 analytical method in which MDSPE employing a zeolite is used to determine
130 NSAIDs in water and urine samples. Several of the main factors affecting the
131 MDSPE have been optimized by a two-step multivariate strategy, using
132 Plackett–Burman and circumscribed central composite designs. Finally, the
133 reported method has been validated and successfully applied to analyse real
134 water and real urine samples.

135

136 **2. Experimental**

137 2.1. Reagents

138 Ketoprofen (KET; 2-(3-benzoylphenyl)propanoic acid), felbinac (FEL; 4-
139 biphenylacetic acid), diclofenac sodium salt (DIC; 2-(2-((2,6-
140 dichlorophenyl)amino)phenyl)acetic acid) and ibuprofen (IBU; 2-(4-
141 isobutylphenyl)propanoic acid) were obtained from Sigma Aldrich (St. Louis,
142 MO, USA). Individual stock standard solutions containing 1000 mg L⁻¹ of KET,
143 FEL, DIC and IBU and mixed stock solutions containing the four NSAIDs (5 and
144 100 mg L⁻¹) were prepared in HPLC-grade methanol from Sigma-Aldrich and
145 were stored in the dark at 4 °C. NSAIDs working solutions (0.5-100 µg L⁻¹) were
146 prepared by proper dilution of mixed stock standard solution with deionized
147 water.

148 HPLC-grade acetonitrile from Sigma-Aldrich, ultrapure water (resistivity of
149 18.2 MΩ cm at 25 °C) obtained from a Millipore Direct System Q5™ purification
150 system from Ibérica S.A. (Madrid, Spain), H₃PO₄ (85% purity) from Scharlau

151 Chemie (Sentmenat, Spain) and KH_2PO_4 pro-analysis from Merck (Darmstadt,
152 Germany) were used to prepare the mobile phase of the LC system.

153 ZSM-5 zeolite (CBV 3024E, $\text{SiO}_2/\text{Al}_2\text{O}_3$ mole ratio=30) in the ammonium
154 nominal cation form was obtained from Zeolyst International (Conshohocken,
155 PA, USA). $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ and $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ reactive grade were obtained from
156 Sigma-Aldrich and NaOH (97% purity, pellets) from Scharlau Chemie.
157 Hexadecyltrimethylammonium bromide (HDTMABr, $\geq 99\%$ purity) from Sigma-
158 Aldrich was employed for preparing a 0.5% (w/v) solution in deionized
159 water/ethanol mixture (50/50, v/v), being HPLC-grade ethanol absolute from
160 Scharlau Chemie.

161 H_3PO_4 , KH_2PO_4 and K_2HPO_4 pro-analysis from Merck were employed for
162 buffering and sodium chloride (99% purity) from Scharlau Chemie was
163 employed to adjust NaCl concentration of water and urine samples prior
164 analysis. Finally, sodium thiosulphate pentahydrate (99.5% purity) from
165 Scharlau Chemie was added to a tap water sample before analysis to remove
166 chlorine interference.

167

168 2.2. Samples

169 Real water samples used were reservoir water from Murcia (Spain),
170 wastewater from a wastewater treatment plant in Barcelona (Spain) and tap
171 water from Barcelona (Spain). Samples were collected in amber glass
172 containers and stored in the dark at 4 °C. As real urine samples, on the one
173 hand, five urine samples were provided by healthy human volunteers, who had
174 not been treated with anyone of the drugs studied. On the other hand, several
175 urine samples were obtained from one volunteer who had been orally treated

176 with ibuprofen (200 mg) to study the applicability of the proposed method. All
177 urine samples were collected in sterile containers and stored at 4 °C.

178 Before use, both water and urine samples were adjusted to pH 2.2 with a
179 buffer solution of 0.0025 M H₃PO₄/0.0029 M KH₂PO₄ and adjusted to 2.5%
180 (w/v) of NaCl concentration. Only tap water was treated with sodium
181 thiosulphate solution (i.e., 33.3 µL of 0.05 M Na₂S₂O₃ was added to 0.1 L of tap
182 water) [46]. Samples were filtered with 0.45 µm pore size nylon filters from
183 Millipore (Madrid, Spain) in order to remove suspended particles before use.
184 Therefore in this case the measurands are the soluble NSAIDs [47]. Water and
185 urine samples were initially analysed under optimized conditions of the
186 proposed method and NSAIDs content was undetectable.

187

188 2.3. Materials and instrumentation

189 A Ni-coated neodymium magnet (S-45-30-N), N45 grade, dimensions
190 45x30 mm from Supermagnete (Gottmadingen, Germany) was used as an
191 external magnetic field. The sample compartment was a 22 mL glass vial with
192 screw top (solid green Melamine cap and PTFE liner) from Supelco (Bellefonte,
193 PA, USA).

194 The chromatographic analysis were performed by an Agilent 1260 Infinity
195 LC system (Agilent Technologies, Waldbronn, Germany), constituted by the
196 following modules: vacuum degasser, quaternary pump (G1311C), autosampler
197 (G1329B), thermostated column compartment (G1316A) and diode array
198 detector (G4212B). Instrumental control and data acquisition and processing
199 were carried out using the software OpenLab (Agilent Technologies). A
200 Kinetex[®] 5 µm EVO C18 100 Å column (150 mm x 4.6 mm i.d.) from

201 Phenomenex (Torrance, California, USA) was used to separate the analytes. A
202 mixture of 0.01 M phosphate buffer (pH = 4.2) and acetonitrile (50:50, v/v) was
203 employed as mobile phase for the separation at a flow rate of 1 mL min⁻¹. The
204 injection volume was 20 µL. The detection was performed at 225 nm for IBU
205 and DIC and 258 nm for KET and FEL.

206 Magnetic susceptibility measurements were performed at 300 K in the
207 magnetic field range -50 to 50 kOe using a MPMS XL (SQUID) magnetometer
208 from Quantum Design (San Diego, CA, USA) for composite characterization
209 (i.e., HDTMA-modified ZSM-5/Fe₂O₃).

210

211 2.4. Synthesis of ZSM-5/Fe₂O₃ composite

212 Synthesis of ZSM-5/Fe₂O₃ composite, described in detail in our previous
213 work [48], was performed in a ZSM-5/Fe₂O₃ weight ratio of 3:1. This weight ratio
214 was chosen to avoid a decrease in available surface area and for ease of
215 composite manipulation under a magnetic field [48]. Briefly, the composite was
216 prepared from a suspension of 3 g of ZSM-5 zeolite in 250 mL solution with
217 FeCl₃·6H₂O (2.335 g) and FeSO₄·7H₂O (1.201 g). Then, 15 mL of 5 M NaOH
218 was added dropwise to precipitate the iron oxide. The mixture was stirred at
219 room temperature for 2 h. The composite was separated from the solution using
220 a Ni-coated neodymium magnet as external magnetic field. The obtained
221 composite was washed with deionized water until washing water became clear
222 at neutral pH. Lastly, the composite was dried at 110 °C overnight.

223

224 2.5. Modification of ZSM-5/Fe₂O₃ composite

225 The modification of ZSM-5/Fe₂O₃ composite with HDTMABr surfactant was

226 described in detail in a previous work [49]. Briefly, surfactant modification
227 consisted in firstly, stirring 10 g of ZSM-5/Fe₂O₃ composite with 150 mL of the
228 HDTMABr solution (0.5%, w/v) for 24 h at room temperature. Secondly,
229 HDTMA-modified ZSM-5/Fe₂O₃ composite (i.e., HDTMA-ZSM-5/Fe₂O₃) was
230 filtered in a Büchner funnel connected to a vacuum pump and washed with
231 deionized water several times. And finally, the obtained composite was dried at
232 120 °C for 3 h.

233 The structure of ZSM-5/Fe₂O₃ composite modified with HDTMABr
234 surfactant is schematically shown in Fig. 1. It can be observed that the
235 HDTMABr surfactant forms a bilayer on the external surface of the zeolite. This
236 occurs when the concentration of the surfactant exceeds its CMC. The CMC of
237 HDTMABr is 0.9 mmol L⁻¹ at 25 °C [42] and in our case, surfactant
238 concentration has 13.7 mmol L⁻¹, being the surfactant concentration 15 times
239 higher than its CMC. Therefore, the formation of HDTMA bilayer can be
240 confirmed. Briefly, this modification was carried out by as follows: firstly, the
241 surfactant is sorbed on the zeolite by cation exchange (i.e., the exchange
242 capacity of the mineral surface for surfactant depends on the external cation
243 exchange capacity (ECEC) [52]) forming a monolayer or “hemimicelle”, but if
244 the surfactant concentration in solution exceeds the CMC, as in this case, then
245 the hydrophobic tails of the surfactant molecules associate to form a bilayer or
246 “admicelle” [53]. This bilayer formation results in a charge reversal on the
247 external surface of zeolite from negative to positive and the positively charged
248 outward-pointing head groups of HDTMA bilayers are balanced by bromide
249 counterions [54,55].

250

251

252 2.6. Magnetic dispersive solid-phase extraction

253 Firstly, 40 mg of HDTMA-ZSM-5/Fe₂O₃ composite were placed in a 22 mL
254 vial glass. Then, 20 mL of standard solution or sample solution adjusted to pH
255 2.2 and 2.5% of NaCl concentration was added and the mixture was shaken
256 vigorously for 2 min. After extraction, the composite was separated from the
257 solution using a Ni-coated neodymium magnet. A glass pipette was used to
258 remove the aqueous phase. Then, the adsorbed analytes were eluted with 424
259 µL of methanol using an ultrasonic bath for 2 min. Finally, eluate was separated
260 from the composite using again the neodymium magnet, withdrawn with a
261 syringe, filtered with 0.22 µm pore size nylon filters and transferred to a vial for
262 further determination by LC-DAD.

263

264 2.7. Data processing

265 A multivariate approach was used to determine the optimum conditions for
266 MDSPE. Firstly, a Plackett-Burman design was used as a screening study to
267 identify the significant factors. Then, a circumscribed central composite design
268 (CCCD) was employed to optimize the significant ones. The statistical software
269 mainly used to build the experiment matrices and evaluate the experimental
270 results in Plackett-Burman and CCC designs (i.e., response surfaces) was
271 NEMRODW[®] (“New Efficient Methodology for Research using Optimal Design”)
272 (LPRAI, Marseille, France). In addition, the statistical software Statgraphics[®]
273 Centurion (Statpoint Technologies Warreton, USA) was used as supplementary
274 support to evaluate the significant factors of CCCD using Pareto chart and to
275 compare the optimum value with the one obtained with NEMRODW[®]. A 20 mL
276 of an aqueous standard with 100 µg L⁻¹ of KET, FEL, DIC and IBU was used for
277 the optimization MDSPE experiments. Peak areas of KET, FEL, DIC and IBU

278 obtained with LC-DAD were individually used as response functions for
279 optimization.

280

281 **3. Results and discussion**

282 3.1. Characterization of HDTMA-ZSM-5/ Fe₂O₃ composite

283 In our previous work [49], X-ray photoelectron spectroscopy (XPS) and
284 attenuated total reflectance-Fourier transform infrared (ATR-FTIR) were used to
285 investigate the oxidation state of Fe in ZSM-5/Fe₂O₃ and the loading of
286 HDTMABr surfactant on ZSM-5/Fe₂O₃, respectively. Fig. S1 shows the
287 magnetic susceptibility of the studied HDTMA-ZSM-5/Fe₂O₃ at 300 K in the
288 magnetic field range -50 to 50 kOe. The magnetization curve shows a sigmoid
289 shape that passes approximately through the origin with an extremely thin
290 hysteresis loop. In addition, the values of coercivity field (H_c) and residual
291 magnetization (M_R) are very small, 6 Oe and 0.08 emu g⁻¹, respectively.
292 Therefore, it could be concluded that the synthesized Fe₂O₃ presents a
293 superparamagnetic behaviour at room temperature [56].

294

295 3.2. Preliminary experiments

296 3.2.1. Extraction efficiency of composites

297 The effect of two composites (i.e., ZSM-5/Fe₂O₃ and HDTMA-ZSM-5/Fe₂O₃)
298 for the extraction of KET, FEL, DIC and IBU was studied preliminarily in
299 aqueous standards (data showed in Fig. S2). Extraction experiments were
300 carried out by shaking 50 mg of each composite in 20 mL of aqueous standard
301 with 500 µg L⁻¹ of KET, FEL, DIC and IBU for 5 min. After extraction, the
302 aqueous standard was removed and sorbents were eluted with 500 µL of
303 methanol using an ultrasonic bath for 3 min. Fig. S2 shows that the signal

304 obtained with HDTMA-ZSM-5/Fe₂O₃ was much higher than the signal obtained
305 with ZSM-5/Fe₂O₃ for all analytes. In the case of ZSM-5/Fe₂O₃, the analytes
306 were retained in the composite pores; however, NSAIDs adsorption was
307 negligible. In the case of HDTMA-ZSM-5/Fe₂O₃, the high adsorption efficiency
308 of NSAIDs was attributed to zeolite surface modification with HDTMABr
309 surfactant, which increased hydrophobicity of the sorbent surface and,
310 therefore, provided a high affinity for organic molecules [57,58]. Consequently,
311 HDTMA-ZSM-5/Fe₂O₃ composite was chosen as sorbent.

312 Related to the affinity of the HDTMA-ZSM-5/Fe₂O₃ composite towards the
313 NSAIDs, two parameters commonly used are: the binding capacity (B , $\mu\text{g g}^{-1}$)
314 and distribution coefficients (K_D , L g^{-1}), defined according to the following
315 equations [59]:

$$316 \quad B = \frac{(C_i - C_f)V}{m} \quad (1)$$

$$317 \quad K_D = \frac{(C_i - C_f)V}{C_f m} \quad (2)$$

318 where V represents the volume of the solution (L), C_i is the initial solution
319 concentration ($\mu\text{g L}^{-1}$), C_f is the solution concentration after extraction ($\mu\text{g L}^{-1}$)
320 and m is the mass of sorbent (g). These parameters were calculated using a
321 solution spiked at 10 mg L^{-1} of each NSAID and the results are presented in
322 Table S2. It should be noted that these results are correlated with enrichment
323 factors obtained in Table 1 (i.e., $\text{KET} < \text{FEL} \approx \text{IBU} < \text{DIC}$).

324 The reutilization of HDTMA-ZSM-5/Fe₂O₃ composite was also studied.
325 Three consecutive extractions were carried out using the same composite and
326 results showed that the sorbent was still extracting NSAIDs but extraction
327 efficiency for all analytes decreased around 15% approximately from first

328 extraction to the second one. This could be due to the removal of HDTMABr
329 surfactant in the elution step. Hence, it can be concluded that HDTMA-ZSM-
330 5/Fe₂O₃ composite cannot be reused. However, this is not an inconvenient
331 since the sorbent (i.e., zeolite) is of low cost and composite synthesis (i.e.,
332 HDTMA-ZSM-5/Fe₂O₃) is very simple.

333

334 3.2.2. Elution solvent nature

335 In this study, based on previous experiences [4,60], the type of eluent
336 solvent was investigated. It should be mentioned that this factor was not include
337 in the screening study because the Plackett-Burman design investigates the
338 factors at two levels and, in this case, four solvents were tested. Acetone,
339 ethanol, acetonitrile and methanol were selected for analyte elution from the
340 sorbent. Extraction experiments were performed by shaking 50 mg of HDTMA-
341 ZSM-5/Fe₂O₃ in 20 mL of aqueous standard with 500 µg L⁻¹ of KET, FEL, DIC
342 and IBU for 5 min. After extraction, the aqueous standard was removed and the
343 sorbent was eluted with 500 µL of acetone, ethanol, acetonitrile and methanol
344 using an ultrasonic bath for 3 min. The results are shown in Fig. S3. Acetone,
345 ethanol and acetonitrile obtained a slightly higher peak area than methanol.
346 However, for practicality, methanol was selected as eluent solvent because
347 phase separation performance was better than with the other solvents.

348

349 3.3. Adsorption mechanisms

350 As previously mentioned, the HDTMABr molecules form a bilayer on the
351 external surface of the zeolite (Fig. 1), which results in a reversal charge on the
352 external surface of zeolite providing sites where anions might be retained while

353 neutral species could partition into the hydrophobic cores [61]. Previous works
354 have proposed several adsorption mechanisms for different analytes (i.e., DIC
355 [57,62], IBU [62], tannic acid [63], humic acid [64], bisphenol A [65], among
356 others) by zeolites modified with surfactants. The adsorption mechanisms are
357 described below. First, electrostatic interaction takes place between the
358 positively charged outward-pointing head groups of HDTMA bilayer and the
359 negatively charged NSAIDs molecules [63]. This mechanism is pH dependant,
360 i.e., at pH below the pKa of studied NSAIDs, they are in a neutral form; while
361 when the pH is clearly above the pKa of these analytes, NSAIDs are negatively
362 charged, and there is electrostatic attraction between NSAIDs and positive
363 charge of head groups of HDTMA bilayer. It is important to point out that the
364 optimum pH was 2.2 (section 3.4.2), and the studied NSAIDs have pKa values
365 ranging from 4-5 (Table S1), therefore, the latter mechanism did not take place.
366 The second mechanism that could act in the adsorption of NSAIDs involves π -
367 cation interaction between the aromatic rings of NSAIDs and quaternary
368 ammonium groups of HDTMA bilayer [51]. Thirdly, hydrogen bonding also could
369 play an important role in the adsorption between the nitrogen atoms of HDTMA
370 bilayer and carboxylate groups of NSAIDs molecules since nitrogen atoms may
371 act as hydrogen bonding acceptors and carboxylate groups may act as
372 hydrogen bonding donors [63,64]. Finally, the last mechanism involved
373 hydrophobic interactions between the hydrophobic C chains of HDTMA bilayer
374 and the hydrophobic functional groups of NSAIDs molecules (i.e., aromatic
375 rings) [63]. Therefore, in our case, it is likely the main mechanisms governing
376 the adsorption of NSAIDs onto HDTMA-ZSM-5/Fe₂O composite were: (i) π -
377 cation interaction, (ii) hydrogen bonding and (iii) hydrophobic interactions.

378

379 3.4. MDSPE optimization

380 3.4.1. Screening study

381 Numerous factors can affect extraction yield in the MDSPE procedure.
382 Therefore, optimization through a multivariate approach is recommended. One
383 particular strategy is the Plackett-Burman design, which is a two-level fractional
384 factorial design to study $k=N-1$ factors in N runs, where N is a multiple of 4 [66].
385 This design assumes that the interactions between factors can be ignored;
386 therefore the main effects can be calculated with a reduced number of
387 experiments, saving time and resources. A Plackett-Burman design was used to
388 construct the matrix of experiments, including five factors in eight runs. Based
389 on previous experience of the research group in MDSPE [48,49,67], the factors
390 investigated at two levels in this work were: sample pH, NaCl concentration,
391 extraction time, eluent solvent volume and elution time. The amount of sorbent
392 is another key factor in MDSPE technique, however, this factor was not
393 included in the present study since it was optimized later by fixing the
394 concentration of the analytes at the upper threshold of the working range and
395 fixing the others factors at their optimum values. Table S3 shows the
396 considered experimental factors and levels in the Plackett-Burman design. The
397 eight experiments were randomly carried out using 20 mL of aqueous standard
398 spiked with $100 \mu\text{g L}^{-1}$ of each NSAID. Peak area of each analyte was
399 individually used as response functions.

400 The data obtained were evaluated by ANOVA and the results are showed in
401 the Pareto charts in Fig. 2. The length of each bar is proportional to the relative
402 influence of the corresponding factor, and those bars that exceed reference

403 vertical lines (dashed lines) can be considered significant with 95% probability.
404 In addition, positive and negative bars revealed if the responses increase or
405 decrease, respectively, when passing from a lower to upper level of the
406 corresponding factor. Fig. 2 shows all the Pareto charts present a similar
407 response for each factor, except DIC Pareto chart, where NaCl concentration
408 and elution time have a different effect, however none of them is significant.
409 According to Fig. 2, the significant factors were: sample pH and NaCl
410 concentration for KET (Fig. 2(a)) and eluent solvent volume for KET, FEL and
411 IBU (Fig. 2(a), 2(b) and 2(d)). The sample pH presents a negative effect for all
412 analytes and was significant for KET. The pKa values of KET, FEL, DIC and
413 IBU range from 4-5 (Table S1). At sample pH below their pKa, the studied
414 analytes are neutral molecules; therefore adsorption is due to π -cation
415 interaction, hydrogen bonding and hydrophobic interactions. When the sample
416 pH is above their pKa, the NSAIDs molecules are transformed into their anionic
417 forms; therefore in this case adsorption is mainly due to electrostatic
418 interactions between the negatively charged NSAIDs molecules and positively
419 charged head groups of HDTMA bilayer, in addition to the abovementioned
420 mechanisms. In this case, all analytes presented a negative effect for sample
421 pH. Therefore, the decrease in NSAIDs adsorption when passing from the lower
422 (pH=3) to the upper level (pH=9) might be attributed to the fact that each type of
423 interaction did not present the same significance at the two pH levels. The NaCl
424 concentration presents a negative effect for FEL, IBU and KET, being
425 significant for the latter, and a positive effect for DIC. The effect of this factor will
426 be explained in the next section (section 3.4.2). Extraction time presents a
427 negative effect for all analytes. The negative effect could be due to the fact that

428 the sorption of HDTMABr surfactant on ZSM-5/Fe₂O₃ surface is by cation
429 exchange, so longer agitation time could cause surfactant losses and,
430 therefore, the concentration of analyte remaining in the supernatant is higher. In
431 addition, this negative effect revealed a rapid and effective mass transfer in the
432 proposed MDSPE method (i.e., two minutes were enough to reach the
433 adsorption equilibrium). The eluent solvent volume presents a negative effect
434 for all analytes since the lower the volume of eluent solvent the higher the
435 analyte concentration in the eluate. Finally, the elution time presents a negative
436 effect for all NSAIDs, except for DIC, although it was not significant in any case.
437 For KET, FEL and IBU one possible explanation is that at longer elution times
438 analyte concentration in the eluate is smaller due to one possible degradation of
439 NSAIDs by ultrasounds energy [68]. However, in the case of DIC, the elution
440 time presents a positive effect, which could be explained by additional hydrogen
441 bonding DIC of its amino group, presenting more sites to interact with the
442 sorbent and, therefore, a longer elution time was necessary to break these
443 interactions. According to results obtained from the Plackett-Burman design,
444 sample pH, NaCl concentration and eluent solvent volume were chosen as
445 significant factors. Thus, these factors were optimized in the next optimization
446 step. The other factors (i.e., extraction time and elution time) were fixed at the
447 most convenient level. Both extraction time and elution time were fixed at low
448 level (i.e., 2 min).

449

450 3.4.2. Optimization study

451 Different experimental designs are reported in the literature, many of which
452 are based on the so-called response surface designs. Circumscribed central

453 composite design (CCCD) is one of the most frequently used as response
454 surface designs. This type of design was employed to assess the main effects,
455 interactions effects and quadratic effects of significant factors of a previous
456 screening step (i.e., sample pH, NaCl concentration and eluent solvent volume).
457 It consists of a two-level factorial design (2^k), with a central point which is
458 repeated n times and $2k$ star points, where k is the number of factors to
459 optimize [66]. The value of star points depends on the desired design properties
460 and number of factors. Star points were fixed at $\alpha = \sqrt[4]{2^k} = 1.68$ in order to
461 ensure the rotatability of the model and the central point was repeated five
462 times to ensure its orthogonality [66]. Low, central and high levels, and the star
463 points of the studied factors are shown in Table S4. The overall matrix of CCCD
464 design involved 19 experiments.

465 The data obtained were evaluated by ANOVA test and the effects were
466 shown in response surfaces from NEMROD[®] (Fig. S4-S6) and Pareto charts
467 from Statgraphics[®] (Fig. S7). The repeatability of the central point ($n=5$) was
468 assessed, obtaining coefficients of variation between 2 and 10%. Table S5
469 shows the optimum MDSPE conditions obtained from the response surface,
470 which were confirmed with optimum value obtained from Statgraphics[®]. It can
471 be observed that both, the values obtained for sample pH and those obtained
472 for eluent solvent volume, were similar for all analytes investigated. However,
473 optimum values for NaCl concentration were analyte-dependent and hence a
474 compromise value was chosen in order to select the most favourable conditions
475 for the simultaneous MDSPE procedure of the four NSAIDs investigated. As
476 shown in Fig. S4-S6 and Fig.S7, all three variables considered were significant.
477 Firstly, regarding eluent solvent volume, the response surfaces (Fig. S4)

478 showed higher signals at the lowest eluent solvent volume and Pareto charts
479 confirmed the significant negative effect for all analytes (Fig. S7(a), S7(c) and
480 S7(d)) except for FEL (Fig. S7(b)). According to Table S5, the optimum eluent
481 solvent volume was 424 μL of methanol in all cases. This result can be easily
482 explained since the lower the volume of eluent solvent the higher the analyte
483 concentration in the extract, as previously explained. Secondly, with regard to
484 sample pH, the response surfaces (Fig. S5) showed higher signals at the lowest
485 pH values for all analytes except for DIC (Fig. S5(c)). Same results were
486 obtained with Pareto charts since all analytes except DIC (Fig. S7(c))
487 presented a significant negative effect for sample pH (Fig. S7(a), S7(b) and
488 S7(d)). According to Table S5, the optimum values for the sample pH were 2.4,
489 2.0, 2.5 and 2.0 for KET, FEL, DIC and IBU, respectively. They were very
490 similar, and since pH was not significant for DIC, 2.2 was chosen as the optimal
491 value for sample pH (i.e., compromise value between values of KET, FEL and
492 IBU). Finally, regarding NaCl concentration, the response surface of DIC (Fig.
493 S6(c)) showed that the highest signal was around the high level (i.e., NaCl
494 concentration=4%) and the response surface of KET (Fig. S6(a)) showed higher
495 signals at the lowest NaCl concentration. These results were confirmed by
496 Pareto charts (Fig. S7) since NaCl concentration presented a positive effect for
497 FEL, IBU and DIC, being significant only for the latter (Fig. S7(c)), and a
498 negative effect for KET (Fig. S7(a)). For FEL, IBU and DIC one possible
499 explanation of enhanced adsorption in the presence of NaCl in solution was
500 probably due to the salting out effect decreases NSAIDs solubility in the
501 aqueous sample. Similar results were obtained for bisphenol A [65]. However,
502 in the case of KET, the negative effect might be related with the ketone group,

503 since this analyte is the only one with that functional group. According to Table
504 S5, the optimum NaCl concentration values were 0, 2.7, 3.9 and 3.1 for KET,
505 FEL, DIC and IBU, respectively. A compromise value of 2.5% NaCl was
506 selected as an optimum value since when the NaCl concentration exceeded
507 this value, the KET signal decreased severely.

508

509 3.4.3. Study of sorbent amount

510 The amount of sorbent is also a factor that affects the MDSPE procedure.
511 This factor was not included in optimization studies because the amount of
512 sorbent depends significantly on the analyte concentration. Therefore, the
513 amount of sorbent was studied fixing the concentration of NSAIDs at the upper
514 threshold of the working range (i.e., 400 $\mu\text{g L}^{-1}$). Different amounts of HDTMA-
515 ZSM-5/ Fe_2O_3 (i.e., 10, 20, 30, 40 and 50 mg) were tested to evaluate the effect
516 of the sorbent quantity on the extraction yield of NSAIDs. Extraction
517 experiments were performed under MDSPE optimized conditions. The results
518 are shown in Fig. 3. Peak area of analytes increased on increasing the amount
519 of sorbent from 10 to 40 mg. Then the adsorption of NSAIDs did not increase by
520 increasing the amount of sorbent to 50 mg. Therefore, the sorbent amount of 40
521 mg was selected as the optimum value under the studied concentration.

522 According to the results of the optimization study, the MDSPE optimum
523 conditions selected for simultaneous extraction of KET, FEL, DIC and IBU were:
524 amount of sorbent, 40 mg; sample pH, 2.2; NaCl concentration, 2.5%;
525 extraction time, 2 min; eluent solvent, methanol; elution solvent volume, 424 μL ;
526 and elution time, 2 min.

527

528 3.4. Validation of the method

529 Analytical figures of merit of the proposed method were assessed under
530 MDSPE optimized conditions (Table 1). The working range was from 3.3 to 400
531 $\mu\text{g L}^{-1}$ for KET, from 1.7 to 400 $\mu\text{g L}^{-1}$ for FEL, from 6.6 to 400 $\mu\text{g L}^{-1}$ for DIC
532 and from 9.9 to 400 $\mu\text{g L}^{-1}$ for IBU. The lower concentrations of working ranges
533 were limited by the limit of quantification (LOQ). The resulting calibration curves
534 gave a high level of linearity with correlation coefficients (r) of 0.998 (N=8) for
535 KET, 0.999 (N=8) for FEL, 0.997 (N=7) for DIC and 0.995 (N=6) for IBU.
536 Instrumental measurement sensitivity was estimated by the slope of the
537 calibration curves being $1.74 \pm 0.02 \text{ mAU min } \mu\text{g}^{-1} \text{ L}$, $3.18 \pm 0.05 \text{ mAU min } \mu\text{g}^{-1}$
538 L , $1.38 \pm 0.02 \text{ mAU min } \mu\text{g}^{-1} \text{ L}$ and $1.16 \pm 0.06 \text{ mAU min } \mu\text{g}^{-1} \text{ L}$ for KET, FEL,
539 DIC and IBU, respectively. Method repeatability, expressed as a coefficient of
540 variation (CV), was evaluated by six replicate analyses of aqueous standard at
541 NSAIDs concentrations of 10 and 200 $\mu\text{g L}^{-1}$. CV values ranged between 2 and
542 5% (Table 1). Enrichment factors (EFs) were calculated as the ratio of the
543 signals obtained at 400 $\mu\text{g L}^{-1}$ with and without MDSPE. As shown in Table 1,
544 EFs were similar for FEL, DIC and IBU (i.e., values ranged between 29.7 ± 0.5
545 and 36.4 ± 1.3). However, KET gave lower extraction performance than the
546 other NSAIDs, with an EF value of 26.1 ± 0.6 . The low EF value obtained for
547 KET can be explained by the optimized extraction conditions chosen. Optimum
548 NaCl concentration for KET was 0% (Table S5). However, NaCl concentration
549 of 2.5% was chosen as optimum extraction conditions for the proposed method
550 because NaCl concentration presented a positive effect for FEL, IBU and DIC,
551 being significant for the latter in CCCD Pareto charts (Fig. S7(c)). The limit of
552 detection (LOD) was determined empirically, progressively measuring more

553 diluted concentrations of the NSAIDs [69,70]. The LOD for each NSAID was the
554 lowest concentration whose signal could be clearly distinguished from blank.
555 The LOD values were 1.0 $\mu\text{g L}^{-1}$, 0.5 $\mu\text{g L}^{-1}$, 2.0 $\mu\text{g L}^{-1}$ and 3.0 $\mu\text{g L}^{-1}$ for KET,
556 FEL, DIC and IBU, respectively.

557

558 3.5. Analysis of real samples

559 The applicability of the proposed method to determine NSAIDs in real water
560 and urine samples was assessed. Three water samples (namely tap water,
561 reservoir water and wastewater) and five urine samples taken from healthy
562 human volunteers were employed to assess matrix effects using recovery
563 studies. Fig. 4 shows typical chromatograms after MDSPE under optimal
564 conditions of samples non-spiked and spiked at 50 $\mu\text{g L}^{-1}$ of each NSAID.
565 Preliminary analyses with the proposed method revealed that none of the
566 selected water and urine samples had initial detectable NSAIDs concentrations
567 (i.e., it can be seen in the chromatograms (a and c)). Consequently, all
568 investigated samples were spiked at two different levels (i.e., 10 and 200 $\mu\text{g L}^{-1}$)
569 and analysed in triplicate. Results are summarized in Table 2 and Table 3 for
570 water and urine samples, respectively. These tables show the relative
571 recoveries determined as the ratio of the signals found after MDSPE in real
572 samples and deionized water spiked at the same concentration levels.

573 For water samples, results showed relative recoveries varying from 86 and
574 107% and CV values ranged between 1 and 8%. And for urine samples, results
575 showed relative recoveries varying from 80 and 112% and CV values ranged
576 between 1 and 14%. It should be noted that obtained relative recoveries for
577 KET in urine samples were lower than those obtained in water samples. It could

578 be due to the effect of ionic strength (i.e., urine samples have a content of salts
579 in their composition which could affect extraction). In addition, initial relative
580 recoveries for DIC in tap water sample were 0 and 36% for 10 and 200 $\mu\text{g L}^{-1}$,
581 respectively. This was corrected by adding sodium thiosulphate to the tap water
582 sample prior analysis to capture free chlorine that might be interacting with DIC
583 [46], obtaining 86 and 106% for DIC at 10 and 200 $\mu\text{g L}^{-1}$, respectively. Finally,
584 according to results, it can be concluded that matrix effects were not significant
585 for the determination of NSAIDs in the studied water and urine samples.

586

587 3.6. Excretion study of IBU in real urine samples

588 The described MDSPE-LC-DAD method was successfully applied to the
589 analysis of urine samples taken from one human volunteer who was orally
590 treated with IBU (200 mg). Urine samples were collected at 0, 2, 3, 4, 6 and 8 h
591 after drug administration. Fig. S8 shows the concentration-time curve of IBU. As
592 can be seen, the urinary excretion of IBU increases to a maximum and then
593 decreases, reaching maximum urinary excretion of the drug at 3 h post IBU
594 dosing. IBU was detected in human urine between 2 h and 8 h at a
595 concentration ranging from $97 \pm 2 \mu\text{g L}^{-1}$ to $1087.1 \pm 1.0 \mu\text{g L}^{-1}$ ($n=3$) and the
596 mean IBU concentration in urine during this time period was $447 \pm 4 \mu\text{g L}^{-1}$.

597

598 3.7. Comparison with other methods

599 For comparative purposes, the characteristics of previously reported
600 MDSPE-based methods using different magnetic sorbents to determine NSAIDs
601 in water and urine samples are summarized in Table 4. As can be seen, the
602 proposed method has the shortest extraction time. In some cases the difference

603 is outstanding, for instance, the methods developed by Li Xu et al. [31,32],
604 require 45 min to extract the analytes whereas in our method 2 min were
605 enough to reach adsorption equilibrium, which indicates the rapid and effective
606 mass transfer of the proposed method. The amount of sorbent in our work is
607 comparable to those in previous works. However, the sorbent used in this work
608 (i.e., HDTMA-ZSM-5/Fe₂O₃) has numerous advantages over the other sorbents.
609 On the one hand, in previous works magnetic nanoparticles were solvothermally
610 synthesized [31,32,71] or heated under N₂ atmosphere [34,51], while in this
611 work they were synthesized at room temperature. On the other hand, in most
612 reported methods sorbent modification is a tedious and time-consuming
613 process including the use toxic organic solvents. The empirical LODs of this
614 work are similar or slightly higher than those obtained in previous publications
615 using statistical methods (i.e., calculated using signal-to-noise ratio or the
616 standard deviation of the blank). It should be pointed that the empirical method
617 provided much more realistic LOD values [69]. Finally, extraction recoveries
618 were comparable to those obtained in previous publications.

619

620 **4. Conclusions**

621 A simple, fast, economical and user-friendly MDSPE-LC-DAD method has
622 been developed to determine NSAIDs in water and urine samples. The
623 proposed sorbent is HDTMA-ZSM-5/Fe₂O₃ composite, based on ZSM-5 zeolite
624 decorated with iron oxide magnetic nanoparticles and modified with HDTMABr
625 surfactant. Due to its magnetic properties, not only is the sorbent easy to handle
626 but also the method is time-saving since filtration and centrifugation steps are
627 unnecessary. The simple modification with a cationic surfactant provides high

628 extraction capacity and rapid extraction. In addition, the sorbent is economical
629 since zeolites are low cost materials, be they synthetic or of natural origin.

630 The applicability of the proposed method has been successfully tested to
631 extract NSAIDs from water and urine samples. Finally, the method enabled
632 subsequent analysis of urine samples taken from one human volunteer orally
633 treated with IBU. These results show the proposed method is applicable to
634 urinary monitoring.

635

636 **Acknowledgements**

637 The authors would like to thank the Spanish Ministry of Economy and
638 Competitiveness and European Union (FEDER funds) (project n. CTQ2016-
639 79991-R) for the financial support. P. Baile also thanks Ministry of Education,
640 Culture and Sports for her FPU grant (FPU14/04589).

641

642 **References**

- 643 [1] I. Pountos, T. Georgouli, H. Bird, P.V. Giannoudis, Nonsteroidal anti-
644 inflammatory drugs: Prostaglandins, indications, and side effects, *Int. J.*
645 *Interf. Cytokine Mediat. Res.* 3 (2011) 19-27.
646 <https://doi.org/10.2147/IJICMR.S10200>.
- 647 [2] C.K.S. Ong, P. Lirk, C.H. Tan, R.A. Seymour, An evidence-based update
648 on nonsteroidal anti-inflammatory drugs, *Clin. Med. Res.* 5 (2007) 19–34.
649 <https://doi.org/10.3121/cmr.2007.698>.
- 650 [3] J.M. Misurac, C.A. Knoderer, J.D. Leiser, C. Nailescu, A.C. Wilson, S.P.
651 Andreoli, Nonsteroidal anti-inflammatory drugs are an important cause of
652 acute kidney injury in children, *J. Pediatr.* 162 (2013) 1153–1159.
653 <https://doi.org/10.1016/j.jpeds.2012.11.069>.
- 654 [4] S. Magiera, Ş. Gülmez, A. Michalik, I. Baranowska, Application of
655 statistical experimental design to the optimisation of microextraction by
656 packed sorbent for the analysis of nonsteroidal anti-inflammatory drugs in
657 human urine by ultra-high pressure liquid chromatography, *J.*
658 *Chromatogr. A* 1304 (2013) 1–9.
659 <https://doi.org/10.1016/j.chroma.2013.06.047>.
- 660 [5] M. Petrović, M.D. Hernando, M.S. Díaz-Cruz, D. Barceló, Liquid
661 chromatography-tandem mass spectrometry for the analysis of
662 pharmaceutical residues in environmental samples: A review, *J.*
663 *Chromatogr. A* 1067 (2005) 1–14.
664 <https://doi.org/10.1016/j.chroma.2004.10.110>.
- 665 [6] I. Rodríguez, J.B. Quintana, R. Cela, R.A. Lorenzo, A.M. Carro, J.
666 Carpinteiro, Solid-phase microextraction with on-fiber derivatization for

- 667 the analysis of anti-inflammatory drugs in water samples, *J. Chromatogr.*
668 *A* 1024 (2004) 1–8. <https://doi.org/10.1016/j.chroma.2003.10.049>.
- 669 [7] J. Debska, A. Kot-Wasik, J. Namiesnik, Determination of nonsteroidal
670 antiinflammatory drugs in water samples using liquid chromatography
671 coupled with diode-array detector and mass spectrometry, *J. Sep. Sci.* 28
672 (2005) 2419–2426. <https://doi.org/10.1002/jssc.200400055>.
- 673 [8] S.S. Zunngu, L.M. Madikizela, L. Chimuka, P.S. Mdluli, Synthesis and
674 application of a molecularly imprinted polymer in the solid-phase
675 extraction of ketoprofen from wastewater, *Comptes Rendus Chim.* 20
676 (2017) 585–591. <https://doi.org/10.1016/j.crci.2016.09.006>.
- 677 [9] T. Wang, S. Liu, G. Gao, P. Zhao, N. Lu, X. Lun, X. Hou, Magnetic solid
678 phase extraction of non-steroidal anti-inflammatory drugs from water
679 samples using a metal organic framework of type $\text{Fe}_3\text{O}_4/\text{MIL-101}(\text{Cr})$, and
680 their quantitation by UPLC-MS/MS, *Microchim. Acta* 184 (2017) 2981–
681 2990. <https://doi.org/10.1007/s00604-017-2319-8>.
- 682 [10] G.G. Noche, M.E.F. Laespada, J.L.P. Pavón, B.M. Cordero, S.M.
683 Lorenzo, Microextraction by packed sorbent for the analysis of
684 pharmaceutical residues in environmental water samples by in situ
685 derivatization-programmed temperature vaporizer-gas chromatography-
686 mass spectrometry, *J. Chromatogr. A* 1218 (2011) 9390–9396.
687 <https://doi.org/10.1016/j.chroma.2011.10.094>.
- 688 [11] H. Alinezhad, A. Amiri, M. Tarahomi, B. Maleki, Magnetic solid-phase
689 extraction of non-steroidal anti-inflammatory drugs from environmental
690 water samples using polyamidoamine dendrimer functionalized with

- 691 magnetite nanoparticles as a sorbent, *Talanta* 183 (2018) 149–157.
692 <https://doi.org/10.1016/j.talanta.2018.02.069>.
- 693 [12] T. Martinez-Sena, S. Armenta, M. de la Guardia, F.A. Esteve-Turrillas,
694 Determination of non-steroidal anti-inflammatory drugs in water and urine
695 using selective molecular imprinted polymer extraction and liquid
696 chromatography, *J. Pharm. Biomed. Anal.* 131 (2016) 48–53.
697 <https://doi.org/10.1016/j.jpba.2016.08.006>.
- 698 [13] A. Gentili, Determination of non-steroidal anti-inflammatory drugs in
699 environmental samples by chromatographic and electrophoretic
700 techniques, *Anal. Bioanal. Chem.* 387 (2007) 1185–1202.
701 <https://doi.org/10.1007/s00216-006-0821-7>.
- 702 [14] A.I. Olives, V. Gonzalez-Ruiz, M.A. Martin, Isolation and quantitative
703 methods for analysis of non-steroidal anti-inflammatory drugs,
704 *Antiinflamm. Antiallergy. Agents Med. Chem.* 11 (2012) 65–95.
705 <https://doi.org/10.2174/187152312803476273>.
- 706 [15] A. Kretschmer, M. Giera, M. Wijtmans, L. de Vries, H. Lingeman, H. Irth,
707 W.M.A. Niessen, Derivatization of carboxylic acids with 4-APEBA for
708 detection by positive-ion LC-ESI-MS(/MS) applied for the analysis of
709 prostanoids and NSAID in urine, *J. Chromatogr. B Anal. Technol. Biomed.*
710 *Life Sci.* 879 (2011) 1393–1401.
711 <https://doi.org/10.1016/j.jchromb.2010.11.028>.
- 712 [16] T. Kosjek, E. Heath, A. Krbavčič, Determination of non-steroidal anti-
713 inflammatory drug (NSAIDs) residues in water samples, *Environ. Int.* 31
714 (2005) 679–685. <https://doi.org/10.1016/j.envint.2004.12.001>.

- 715 [17] N.H. Hashim, S.J. Khan, Enantioselective analysis of ibuprofen,
716 ketoprofen and naproxen in wastewater and environmental water
717 samples, *J. Chromatogr. A* 1218 (2011) 4746–4754.
718 <https://doi.org/10.1016/j.chroma.2011.05.046>.
- 719 [18] L.M. Madikizela, L. Chimuka, Determination of ibuprofen, naproxen and
720 diclofenac in aqueous samples using a multi-template molecularly
721 imprinted polymer as selective adsorbent for solid-phase extraction, *J.*
722 *Pharm. Biomed. Anal.* 128 (2016) 210–215.
723 <https://doi.org/10.1016/j.jpba.2016.05.037>.
- 724 [19] B. Suárez, B.M. Simonet, S. Cárdenas, M. Valcárcel, Determination of
725 non-steroidal anti-inflammatory drugs in urine by combining an
726 immobilized carboxylated carbon nanotubes minicolumn for solid-phase
727 extraction with capillary electrophoresis-mass spectrometry, *J.*
728 *Chromatogr. A* 1159 (2007) 203–207.
729 <https://doi.org/10.1016/j.chroma.2007.01.092>.
- 730 [20] J. Płotka-Wasyłka, N. Szczepańska, M. de la Guardia, J. Namieśnik,
731 Miniaturized solid-phase extraction techniques, *Trends Anal. Chem.* 73
732 (2015) 19–38. <https://doi.org/10.1016/j.trac.2015.04.026>.
- 733 [21] M.E. Torres Padrón, Z. Sosa Ferrera, J.J. Santana Rodríguez, Coupling
734 of solid-phase microextraction with micellar desorption and high
735 performance liquid chromatography for the determination of
736 pharmaceutical residues in environmental liquid samples, *Biomed.*
737 *Chromatogr.* 23 (2009) 1175–1185. <https://doi.org/10.1002/bmc.1240>.
- 738 [22] R. Mirzajani, F. Kardani, Z. Ramezani, Preparation and characterization
739 of magnetic metal–organic framework nanocomposite as solid-phase

740 microextraction fibers coupled with high-performance liquid
741 chromatography for determination of non-steroidal anti-inflammatory
742 drugs in biological fluids and tablet formulation samples, *Microchem. J.*
743 144 (2019) 270–284. <https://doi.org/10.1016/j.microc.2018.09.014>.

744 [23] A. Sarafraz-Yazdi, A. Amiri, G. Rounaghi, H. Eshtiagh-Hosseini,
745 Determination of non-steroidal anti-inflammatory drugs in water samples
746 by solid-phase microextraction based sol-gel technique using
747 poly(ethylene glycol) grafted multi-walled carbon nanotubes coated fiber,
748 *Anal. Chim. Acta* 720 (2012) 134–141.
749 <https://doi.org/10.1016/j.aca.2012.01.021>.

750 [24] A. Sarafraz-Yazdi, A. Amiri, G. Rounaghi, H. Eshtiagh-Hosseini,
751 Determination of non-steroidal anti-inflammatory drugs in urine by hollow-
752 fiber liquid membrane-protected solid-phase microextraction based on
753 sol-gel fiber coating, *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.*
754 908 (2012) 67–75. <https://doi.org/10.1016/j.jchromb.2012.09.040>.

755 [25] Y.B. Luo, H.B. Zheng, J.X. Wang, Q. Gao, Q.W. Yu, Y.Q. Feng, An
756 anionic exchange stir rod sorptive extraction based on monolithic material
757 for the extraction of non-steroidal anti-inflammatory drugs in
758 environmental aqueous samples, *Talanta* 86 (2011) 103–108.
759 <https://doi.org/10.1016/j.talanta.2011.08.020>.

760 [26] W. Fan, X. Mao, M. He, B. Chen, B. Hu, Development of novel sol-gel
761 coatings by chemically bonded ionic liquids for stir bar sorptive extraction
762 - application for the determination of NSAIDs in real samples, *Anal.*
763 *Bioanal. Chem.* 406 (2014) 7261–7273. [https://doi.org/10.1007/s00216-](https://doi.org/10.1007/s00216-014-8141-9)
764 [014-8141-9](https://doi.org/10.1007/s00216-014-8141-9).

- 765 [27] A.A. D'Archivio, M.A. Maggi, F. Ruggieri, M. Carlucci, V. Ferrone, G.
766 Carlucci, Optimisation by response surface methodology of
767 microextraction by packed sorbent of non steroidal anti-inflammatory
768 drugs and ultra-high performance liquid chromatography analysis of
769 dialyzed samples, *J. Pharm. Biomed. Anal.* 125 (2016) 114–121.
770 <https://doi.org/10.1016/j.jpba.2016.03.045>.
- 771 [28] V. D'Angelo, F. Tessari, G. Bellagamba, E. de Luca, R. Cifelli, C. Celia, R.
772 Primavera, M. di Francesco, D. Paolino, L. di Marzio, M. Locatelli,
773 Microextraction by packed sorbent and HPLC–PDA quantification of
774 multiple anti-inflammatory drugs and fluoroquinolones in human plasma
775 and urine, *J. Enzyme Inhib. Med. Chem.* 31 (2016) 110–116.
776 <https://doi.org/10.1080/14756366.2016.1209496>.
- 777 [29] M. Šafaříková, I. Šafařík, Magnetic solid-phase extraction, *J. Magn.*
778 *Magn. Mater.* 194 (1999) 108–112. <https://doi.org/10.1016/S0304->
779 [8853\(98\)00566-6](https://doi.org/10.1016/S0304-8853(98)00566-6).
- 780 [30] M. Wierucka, M. Biziuk, Application of magnetic nanoparticles for
781 magnetic solid-phase extraction in preparing biological, environmental
782 and food samples, *Trends Anal. Chem.* 59 (2014) 50–58.
783 <https://doi.org/10.1016/j.trac.2014.04.007>.
- 784 [31] S.W. Xue, J. Li, L. Xu, Preparation of magnetic melamine-formaldehyde
785 resin and its application to extract nonsteroidal anti-inflammatory drugs,
786 *Anal. Bioanal. Chem.* 409 (2017) 3103–3113.
787 <https://doi.org/10.1007/s00216-017-0251-8>.
- 788 [32] L.Y. Ma, Q. Li, J. Li, L. Xu, Preparation of highly hydrophilic magnetic
789 nanoparticles with anion-exchange ability and their application for the

790 extraction of non-steroidal anti-inflammatory drugs in environmental
791 samples, *J. Sep. Sci.* 41 (2018) 678–688.
792 <https://doi.org/10.1002/jssc.201700881>.

793 [33] M. Amiri, Y. Yamini, M. Safari, H. Asiabi, Magnetite nanoparticles coated
794 with covalently immobilized ionic liquids as a sorbent for extraction of non-
795 steroidal anti-inflammatory drugs from biological fluids, *Microchim. Acta*
796 183 (2016) 2297–2305. <https://doi.org/10.1007/s00604-016-1869-5>.

797 [34] A.A. Asgharinezhad, H. Ebrahimzadeh, Poly(2-aminobenzothiazole)-
798 coated graphene oxide/magnetite nanoparticles composite as an efficient
799 sorbent for determination of non-steroidal anti-inflammatory drugs in urine
800 sample, *J. Chromatogr. A* 1435 (2016) 18–29.
801 <https://doi.org/10.1016/j.chroma.2016.01.027>.

802 [35] V. Ferrone, M. Carlucci, V. Ettore, R. Cotellese, P. Palumbo, A. Fontana,
803 G. Siani, G. Carlucci, Dispersive magnetic solid phase extraction
804 exploiting magnetic graphene nanocomposite coupled with UHPLC-PDA
805 for simultaneous determination of NSAIDs in human plasma and urine, *J.*
806 *Pharm. Biomed. Anal.* 161 (2018) 280–288.
807 <https://doi.org/10.1016/j.jpba.2018.08.005>.

808 [36] S.M. Abd Wahib, W.A. Wan Ibrahim, M.M. Sanagi, M.A. Kamboh, A.S.
809 Abdul Keyon, Magnetic sporopollenin-cyanopropyltriethoxysilane-
810 dispersive micro-solid phase extraction coupled with high performance
811 liquid chromatography for the determination of selected non-steroidal anti-
812 inflammatory drugs in water samples, *J. Chromatogr. A* 1532 (2017) 50–
813 57. <https://doi.org/10.1016/j.chroma.2017.11.059>.

- 814 [37] P. Baile, E. Fernández, L. Vidal, A. Canals, Zeolites and zeolite-based
815 materials in extraction and microextraction techniques, *Analyst* 144
816 (2019) 366–387. <https://doi.org/10.1039/c8an01194j>.
- 817 [38] S.M. Auerbach, K.A. Carrado, P.K. Dutta, *Handbook of zeolite science
818 and technology*, first ed., Marcel Dekker, New York, 2003.
- 819 [39] W.J. Roth, D. Kubička, J. Čejka, Zeolites in the 21st Century, in: B.
820 Trewyn (Ed.), *Heterogeneous catalysis for today's challenges: Synthesis,
821 characterization and applications*, Royal Society of Chemistry Publishing,
822 Cambridge, 2015, pp. 77-99.
- 823 [40] M.G. Valdés, A.I. Pérez-Cordoves, M.E. Díaz-García, Zeolites and
824 zeolite-based materials in analytical chemistry, *Trends Anal. Chem.* 25
825 (2006) 24–30. <https://doi.org/10.1016/j.trac.2005.04.016>.
- 826 [41] P. Chutia, S. Kato, T. Kojima, S. Satokawa, Adsorption of As(V) on
827 surfactant-modified natural zeolites, *J. Hazard. Mater.* 162 (2009) 204–
828 211. <https://doi.org/10.1016/j.jhazmat.2008.05.024>.
- 829 [42] P. Arnnok, N. Patdhanagul, R. Burakham, An on-line admicellar SPE-
830 HPLC system using CTAB-modified zeolite NaY as sorbent for
831 determination of carbamate pesticides in water, *Chromatographia* 78
832 (2015) 1327–1337. <https://doi.org/10.1007/s10337-015-2965-0>.
- 833 [43] T. Pasinli, O. Henden, Solid phase extraction of zearalenone (ZEN) from
834 beer samples using natural zeolite clinoptilolite and organo-zeolites prior
835 to HPLC determination, *Ekoloji* 22 (2015) 57–66.
836 <https://doi.org/10.5053/ekoloji.2013.897>.

- 837 [44] P. Arnnok, R. Burakham, Retention of carbamate pesticides by different
838 surfactant-modified sorbents: A comparative study, *J. Braz. Chem. Soc.*
839 25 (2014) 1720–1729. <https://doi.org/10.5935/0103-5053.20140167>.
- 840 [45] P. Salisaeng, P. Arnnok, N. Patdhanagul, R. Burakham, Vortex-assisted
841 dispersive micro-solid phase extraction using CTAB-modified zeolite NaY
842 sorbent coupled with HPLC for the determination of carbamate
843 insecticides, *J. Agric. Food Chem.* 64 (2016) 2145–2152.
844 <https://doi.org/10.1021/acs.jafc.5b05437>.
- 845 [46] M. Terasaki, M. Makino, Determination of chlorinated by-products of
846 parabens in swimming pool water, *Int. J. Environ. Anal. Chem.* 88 (2008)
847 911–922. <https://doi.org/10.1080/03067310802272663>.
- 848 [47] A. Rodrigues, A. Brito, P. Janknecht, M.F. Proena, R. Nogueira,
849 Quantification of humic acids in surface water: Effects of divalent cations,
850 pH, and filtration, *J. Environ. Monit.* 11 (2009) 377–382.
851 <https://doi.org/10.1039/b811942b>.
- 852 [48] E. Fernández, L. Vidal, A. Canals, Zeolite/iron oxide composite as sorbent
853 for magnetic solid-phase extraction of benzene, toluene, ethylbenzene
854 and xylenes from water samples prior to gas chromatography-mass
855 spectrometry, *J. Chromatogr. A* 1458 (2016) 18–24.
856 <https://doi.org/10.1016/j.chroma.2016.06.049>.
- 857 [49] P. Baile, L. Vidal, M.A. Aguirre, A. Canals, A modified ZSM-5
858 zeolite/Fe₂O₃ composite as a sorbent for magnetic dispersive solid-phase
859 microextraction of cadmium, mercury and lead from urine samples prior to
860 inductively coupled plasma optical emission spectrometry, *J. Anal. At.*
861 *Spectrom.* 33 (2018) 856–866. <https://doi.org/10.1039/c7ja00366h>.

- 862 [50] M. Anari-Anaraki, A. Nezamzadeh-Ejhieh, Modification of an Iranian
863 clinoptilolite nano-particles by hexadecyltrimethyl ammonium cationic
864 surfactant and dithizone for removal of Pb(II) from aqueous solution, J.
865 Colloid Interface Sci. 440 (2015) 272–281.
866 <https://doi.org/10.1016/j.jcis.2014.11.017>.
- 867 [51] A.A. Asgharinezhad, N. Mollazadeh, H. Ebrahimzadeh, F. Mirbabaei, N.
868 Shekari, Magnetic nanoparticles based dispersive micro-solid-phase
869 extraction as a novel technique for coextraction of acidic and basic drugs
870 from biological fluids and waste water, J. Chromatogr. A 1338 (2014) 1–8.
871 <https://doi.org/10.1016/j.chroma.2014.02.027>.
- 872 [52] E.J. Sullivan, J.W. Carey, R.S. Bowman, Thermodynamics of cationic
873 surfactant sorption onto natural clinoptilolite, J. Colloid Interface Sci. 206
874 (1998) 369–380. <https://doi.org/10.1006/jcis.1998.5764>.
- 875 [53] S. Wang, Y. Peng, Natural zeolites as effective adsorbents in water and
876 wastewater treatment, Chem. Eng. J. 156 (2010) 11–24.
877 <https://doi.org/10.1016/j.cej.2009.10.029>.
- 878 [54] Y. Zhan, J. Lin, Z. Zhu, Removal of nitrate from aqueous solution using
879 cetylpyridinium bromide (CPB) modified zeolite as adsorbent, J. Hazard.
880 Mater. 186 (2011) 1972–1978.
881 <https://doi.org/10.1016/j.jhazmat.2010.12.090>.
- 882 [55] Z. Li, R.S. Bowman, Counterion effects on the sorption of cationic
883 surfactant and chromate on natural clinoptilolite, Environ. Sci. Technol. 31
884 (1997) 2407–2412. <https://doi.org/10.1021/es9610693>.
- 885 [56] B.K. Sodipo, A.A. Aziz, Recent advances in synthesis and surface
886 modification of superparamagnetic iron oxide nanoparticles with silica, J.

- 887 Magn. Magn. Mater. 416 (2016) 275–291.
888 <https://doi.org/10.1016/j.jmmm.2016.05.019>.
- 889 [57] K. Sun, Y. Shi, X. Wang, Z. Li, Sorption and retention of diclofenac on
890 zeolite in the presence of cationic surfactant, *J. Hazard. Mater.* 323
891 (2017) 584–592. <https://doi.org/10.1016/j.jhazmat.2016.08.026>.
- 892 [58] M. Marković, A. Daković, D. Krajišnik, M. Kragović, J. Milić, A. Langella,
893 B. de Gennaro, P. Cappelletti, M. Mercurio, Evaluation of the
894 surfactant/phillipsite composites as carriers for diclofenac sodium, *J. Mol.*
895 *Liq.* 222 (2016) 711–716. <https://doi.org/10.1016/j.molliq.2016.07.127>.
- 896 [59] P. Luliński, J. Giebułtowicz, P. Wroczyński, D. Maciejewska, A highly
897 selective molecularly imprinted sorbent for extraction of 2-
898 aminothiazoline-4-carboxylic acid – synthesis, characterization
899 and application in post-mortem whole blood analysis, *J. Chromatogr. A*
900 1420 (2015) 16–25. doi:10.1016/j.chroma.2015.09.083.
- 901 [60] S. Kamaruzaman, M.M. Sanagi, S. Endud, W.A. Wan Ibrahim, N. Yahaya,
902 MCM-41 solid phase membrane tip extraction combined with liquid
903 chromatography for the determination of non-steroidal anti-inflammatory
904 drugs in human urine, *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.*
905 940 (2013) 59–65. <https://doi.org/10.1016/j.jchromb.2013.09.017>.
- 906 [61] Z. Li, T. Burt, R.S. Bowman, Sorption of ionizable organic solutes by
907 surfactant-modified zeolite, *Environ. Sci. Technol.* 34 (2000) 3756–3760.
908 <https://doi.org/10.1021/es990743o>.
- 909 [62] R. Pasquino, M. di Domenico, F. Izzo, D. Gaudino, V. Vanzanella, N.
910 Grizzuti, B. de Gennaro, Rheology-sensitive response of zeolite-
911 supported anti-inflammatory drug systems, *Colloids Surfaces B*

912 Biointerfaces 146 (2016) 938–944.
913 <https://doi.org/10.1016/j.colsurfb.2016.07.039>.

914 [63] J. Lin, Y. Zhan, Z. Zhu, Y. Xing, Adsorption of tannic acid from aqueous
915 solution onto surfactant-modified zeolite, *J. Hazard. Mater.* 193 (2011)
916 102–111. <https://doi.org/10.1016/j.jhazmat.2011.07.035>.

917 [64] Y. Zhan, J. Lin, Y. Qiu, N. Gao, Z. Zhu, Adsorption of humic acid from
918 aqueous solution on bilayer hexadecyltrimethyl ammonium bromide-
919 modified zeolite, *Front. Environ. Sci. Eng. China.* 5 (2011) 65–75.
920 <https://doi.org/10.1007/s11783-010-0277-z>.

921 [65] Y. Dong, D. Wu, X. Chen, Y. Lin, Adsorption of bisphenol A from water by
922 surfactant-modified zeolite, *J. Colloid Interface Sci.* 348 (2010) 585–590.
923 <https://doi.org/10.1016/j.jcis.2010.04.074>.

924 [66] D.C. Montgomery, *Design and analysis of experiments*, seventh ed.,
925 Wiley-VCH, New Jersey (USA), 2009.

926 [67] L. Costa dos Reis, L. Vidal, A. Canals, Graphene oxide/Fe₃O₄ as sorbent
927 for magnetic solid-phase extraction coupled with liquid chromatography to
928 determine 2,4,6-trinitrotoluene in water samples, *Anal. Bioanal. Chem.*
929 409 (2017) 2665–2674. <https://doi.org/10.1007/s00216-017-0211-3>.

930 [68] M. Stucchi, G. Cerrato, C.L. Bianchi, Ultrasound to improve both
931 synthesis and pollutants degradation based on metal nanoparticles
932 supported on TiO₂, *Ultrason. Sonochem.* 51 (2019) 462–468.
933 <https://doi.org/10.1016/j.ultsonch.2018.07.011>.

934 [69] D.A. Armbruster, M.D. Tillman, L.M. Hubbs, Limit of detection (LOD)/limit
935 of quantitation (LOQ): Comparison of the empirical and the statistical

936 methods exemplified with GC-MS assays of abused drugs, *Clin. Chem.*
937 40 (1994) 1233–1238.

938 [70] Eurachem Guide, The fitness for purpose of analytical methods: A
939 laboratory guide to method validation and related topics,
940 <https://www.eurachem.org/index.php/publications/guides/mv>, 2014
941 (accessed 13 February 2019).

942 [71] Y. Deng, J. Shen, J. Liu, Y. Wei, C. Wang, A magnetic adsorbent grafted
943 with pendant naphthyl polymer brush for enrichment of the nonsteroidal
944 anti-inflammatory drugs indomethacin and diclofenac, *Microchim. Acta*
945 185 (2018). <https://doi.org/10.1007/s00604-018-2913-4>.

946

947 **Figure captions**

948 **Fig. 1.** Scheme of zeolite surface modified by HDTMABr surfactant adapted
949 from [50] and the probable interactions between the analytes and HDTMA-ZSM-
950 5/Fe₂O₃ composite adapted from [51].

951 **Fig. 2.** Pareto charts of Plackett-Burman design for: (a) KET; (b) FEL; (c) DIC;
952 and (d) IBU.


953 **Fig. 3.** Effect of amount of sorbent. Extraction conditions: concentration of
954 analytes, 400 µg L⁻¹; sample pH, 2.2; NaCl concentration, 2.5%; extraction
955 time, 2 min; eluent solvent, methanol; eluent solvent volume, 424 µL; and
956 elution time, 2 min. The error bars are the standard deviation of three replicates.

957 **Fig. 4.** Typical chromatograms after MDSPE under optimal conditions of
958 samples non-spiked and spiked at 50 µg L⁻¹ of each NSAID: (a) tap water, (b)
959 spiked tap water, (c) urine, and (d) spiked urine. LC-DAD conditions: mobile
960 phase, 0.01 M phosphate buffer (pH = 4.2) and acetonitrile (50:50, v/v); flow
961 rate, 1 mL min⁻¹; injection volume, 20 µL; and wavelength, 225 nm.

962

963


Fig. 1.



964


965

Fig. 2.



969

Fig. 3.




970

971

972

Fig. 4.



973

974

975

TABLES

976 **Table 1.** Analytical figures of merit of the proposed method (MDSPE-LC-DAD).

Analyte	Working range ($\mu\text{g L}^{-1}$)	r^a	Sensitivity ^b (mAU min μg^{-1} L)	CV ^c (%)		LOD ^d ($\mu\text{g L}^{-1}$)	LOQ ^e ($\mu\text{g L}^{-1}$)	EF ^f
				10 $\mu\text{g L}^{-1}$	200 $\mu\text{g L}^{-1}$			
KET	3.3-400	0.998 (8)	1.74 ± 0.02	5	2	1.0	3.3	26.1 ± 0.6
FEL	1.7-400	0.999 (8)	3.18 ± 0.05	2	2	0.5	1.7	32.9 ± 0.9
DIC	6.6-400	0.997 (7)	1.38 ± 0.02	4	3	2.0	6.6	36.4 ± 1.3
IBU	9.9-400	0.995 (6)	1.16 ± 0.06	3	2	3.0	9.9	29.7 ± 0.5

977 ^a Correlation coefficient (r): number of calibration standards in parenthesis.978 ^b Slope \pm standard deviation.979 ^c Coefficient of variation (CV): mean value for 6 replicate analyses of 10 $\mu\text{g L}^{-1}$ and 200 $\mu\text{g L}^{-1}$ spiked solutions.980 ^d Limit of detection (LOD): determined by the empirical approach. The LODs were the lowest concentration whose signal could be
981 clearly distinguished from blank [69,70].982 ^e Limit of quantification (LOQ): calculated as 3.3 times the LOD.983 ^f Enrichment factor (EF). EF: calculated as the ratio of the signals obtained at 400 $\mu\text{g L}^{-1}$ with and without MDSPE.

984

985 **Table 2.** Relative recoveries and CV values (in parentheses) obtained for the analytes in the three studied real water samples.

Analyte	Relative recoveries (%) and CV values in parentheses (%) ^a					
	Tap water		Reservoir water		Wastewater	
	10 µg L ⁻¹	200 µg L ⁻¹	10 µg L ⁻¹	200 µg L ⁻¹	10 µg L ⁻¹	200 µg L ⁻¹
KET	88 (5)	107 (4)	98 (1)	100 (1)	101 (2)	97 (1)
FEL	90 (3)	106 (2)	92 (2)	102 (1)	94 (1)	99 (1)
DIC	86 (4)	105 (4)	101 (1)	96 (1)	100 (1)	94 (2)
IBU	101 (8)	104 (2)	97 (1)	93 (1)	103 (4)	90 (2)

986 ^aThree replicate analyses at indicated spiking levels.

987

988 **Table 3.** Relative recoveries and CV values (in parentheses) obtained for the analytes in the five studied urine samples.

Analyte	Relative recoveries (%) and CV values in parentheses (%) ^a									
	Urine 1		Urine 2		Urine 3		Urine 4		Urine 5	
	10 µg L ⁻¹	200 µg L ⁻¹	10 µg L ⁻¹	200 µg L ⁻¹	10 µg L ⁻¹	200 µg L ⁻¹	10 µg L ⁻¹	200 µg L ⁻¹	10 µg L ⁻¹	200 µg L ⁻¹
KET	80 (8)	84 (1)	85 (9)	88 (10)	87 (3)	87 (3)	85 (14)	95 (3)	85 (7)	94 (2)
FEL	92 (1)	91 (1)	86 (4)	81 (1)	99 (12)	91 (5)	90 (6)	97 (1)	98 (11)	87 (4)
DIC	99 (3)	100 (3)	99 (6)	86 (3)	102 (3)	96 (8)	101 (12)	106 (2)	95 (11)	103 (4)
IBU	112 (4)	102 (11)	107 (4)	88 (14)	111 (6)	87 (8)	107 (6)	107 (1)	90 (13)	98 (6)

989 ^aThree replicate analyses at indicated spiking levels.

990

991 **Table 4.** Comparison of methods based on MDSPE for NSAIDs determination in urine and water samples.

Sorbent	Synthesis MNPs	Sample	Amount of sorbent (mg)	Extraction time (min)	Detection technique	LOD ($\mu\text{g L}^{-1}$)	ER (%) ^a	Ref.
MMFR	Solvothermal method	Urine Milk	20	45	HPLC-UV	0.3 (KET) ^b 0.3 (KET) ^b	78	[31]
Fe ₃ O ₄ @SiO ₂ -MPTMS-DDA	Solvothermal method	Water	20	45	HPLC-UV	1.5-3.0 (KET) ^b	64	[32]
PNA grafted MNPs	Solvothermal method	Water	10	5	HPLC-UV	0.64 DIC ^b	-	[71]
GO/Fe ₃ O ₄ @PABT	Heating under N ₂ atmosphere	Urine	16	-	HPLC-DAD	0.2 (DIC) ^b 0.3 (IBU) ^b	86 90	[34]
Fe ₃ O ₄ @decanoic acid nanoparticles	Heating under N ₂ atmosphere	Water Plasma Urine	10	5	HPLC-UV	1.5 (DIC) ^b 3.5 (DIC) ^b 4.5 (DIC) ^b	77 64 67	[51]
MS-CNPrTEOS	Room temperature	Water	40	10	HPLC-UV	0.29-0.45 (KET) ^c 0.24-0.29 (DIC) ^c 0.51-0.34 (IBU) ^c	83-92 72-73 75-87	[36]
HDTMA-ZSM-5/Fe ₂ O ₃	Room temperature	Water Urine	40	2	LC-DAD	1.0 (KET) ^d 0.5 (FEL) ^d 2.0 (DIC) ^d 3.0 (IBU) ^d	55 70 77 64	This work

992 ^aExtraction recovery (ER(%)): it was calculated by the following equation, $ER(\%) = EF \cdot \frac{volume_{final}}{volume_{initial}} \cdot 100$

993 ^bCalculated as a signal-to-noise ratio equal to 3.

994 ^cCalculated using $3s_{blank}/m$, where s_{blank} is the standard deviation of blank and m is a slope of the calibration curve.

995 ^dDetermined by the empirical approach. The LODs were the lowest concentration whose signal could be clearly distinguished from
996 blank [69,70].

997 MNPs, magnetic nanoparticles; MMFR, magnetic melamine-formaldehyde resin; HPLC-UV, high performance liquid chromatography-ultraviolet; KET,
998 ketoprofen; Fe₃O₄@SiO₂-MPTMS-DDA, diallyldimethylammonium chloride modified magnetite nanoparticles; PNA grafted MNPs, Poly(2-naphthyl acrylate)
999 grafted magnetic nanoparticles; DIC, diclofenac; GO/Fe₃O₄@PABT, Poly(2-aminobenzothiazole)-coated graphene oxide/magnetite nanoparticles; HPLC-DAD,
1000 high performance liquid chromatography-diode array detector; IBU, ibuprofen; MS-CNPrTEOS, magnetic sporopollenin-cyanopropyltriethoxysilane.